An anti-myostatin antibody can mean two very different things: a lab reagent used to detect myostatin, or a clinical antibody designed to change myostatin signaling in people. Search results often mix those categories.
Key takeaways
- Lab anti-myostatin antibodies are research tools, not therapies.
- Clinical antibodies have produced mixed results: some changed muscle size or lean mass, but functional outcomes have often disappointed.
- MYO-029, domagrozumab, BMS-986089, and LY2495655 are important because they show how difficult translation has been.
- Newer candidates aim for better selectivity, different forms of myostatin, or lean-mass preservation during obesity treatment.
- None of these should be treated as legal, routine bodybuilding products.
Quick comparison
| Name | What it targeted | Main context | Evidence takeaway |
|---|---|---|---|
| MYO-029 / stamulumab | Mature myostatin | Muscular dystrophies | Early human safety; no clear functional breakthrough |
| Domagrozumab / PF-06252616 | Myostatin | Duchenne muscular dystrophy | Increased muscle volume signals, but no meaningful functional benefit |
| BMS-986089 / taldefgrobep alfa | Myostatin pathway | Duchenne and SMA contexts | Mixed history; newer SMA work focused on motor function |
| LY2495655 / landogrozumab | Myostatin | Sarcopenia, hip fracture, cachexia research | Lean-mass signals varied; function remained hard |
| Trevogrumab / REGN1033 | Myostatin / GDF8 | Obesity with semaglutide | Lean-mass preservation and fat-loss quality are the focus |
| Apitegromab | Pro- and latent myostatin | Spinal muscular atrophy | Clinically important SMA candidate; not a bodybuilding antibody |
For a broader clinical overview, read myostatin inhibitor drugs and myostatin inhibitors in humans.
Lab antibodies versus therapeutic antibodies
Many search results for "anti-myostatin antibody" are catalog pages from reagent suppliers. These antibodies are used to detect myostatin in Western blotting, immunohistochemistry, ELISA, or other assays.
That is different from a therapeutic monoclonal antibody. A lab antibody may bind a protein well enough for detection but have no clinical formulation, dosing, pharmacokinetics, safety package, or treatment indication.
If a page sells an antibody and lists applications such as WB, IHC, ELISA, IP, or flow cytometry, it is probably a research reagent.
MYO-029: the early human test
MYO-029, also called stamulumab, was one of the first anti-myostatin antibodies tested in people with muscular dystrophy. It neutralized myostatin so it could not bind its receptor normally.
The trial helped establish that systemic myostatin targeting was possible, but it did not create a clear functional win. That pattern would repeat across several programs: the biology was plausible, but translating it into meaningful strength or daily function was difficult.
MYO-029 remains useful as a reference point. It showed promise was not enough.
Domagrozumab: size signals without the needed outcome
Domagrozumab was developed for Duchenne muscular dystrophy. Preclinical work and early signals made sense: block myostatin, support muscle growth, and possibly help boys with a progressive muscle-wasting disease.
The problem was the clinical endpoint. Later studies did not show the functional benefit needed to justify continued development. This is one reason modern myostatin articles should avoid saying "more muscle" as if it automatically means better function.
The lesson is not that myostatin does not matter. The lesson is that a disease, drug, endpoint, and patient population must all line up.
BMS-986089 and taldefgrobep alfa
BMS-986089 is tied to taldefgrobep alfa, a myostatin-pathway candidate with an Fc-fusion/adnectin-style design rather than a simple supplement-like blocker.
This category is easy to misread because "anti-myostatin" can refer to different mechanisms: binding active myostatin, interfering with receptor activation, or changing pathway signaling more broadly.
In spinal muscular atrophy, taldefgrobep alfa has been studied as a muscle-directed add-on concept. That is different from claiming it is a physique drug.
LY2495655 / landogrozumab
LY2495655, also known as landogrozumab, is another anti-myostatin antibody that appeared in muscle-loss research, including older-adult and cachexia-related contexts.
The important point is endpoint discipline. Lean mass, stair climbing, gait speed, fall risk, fatigue, survival, and quality of life are not the same outcome. A myostatin antibody can move one without proving all the others.
Trevogrumab and obesity treatment
Trevogrumab, also called REGN1033, is a human antibody against GDF8/myostatin. Its current interest is not classic bodybuilding. It is lean-mass preservation during GLP-1-based weight loss.
Regeneron reported phase 2 data in which semaglutide plus trevogrumab reduced lean-mass loss compared with semaglutide alone, while combination strategies changed fat-mass outcomes. That is a very specific use case: the quality of weight loss under clinical supervision.
Do not read those results as permission to seek an antibody for gym use.
Apitegromab: selective latent-myostatin strategy
Apitegromab is not usually described as a classic anti-mature-myostatin antibody. It targets pro- and latent myostatin to prevent activation of mature myostatin.
Its lead use case is spinal muscular atrophy. Phase 3 SAPPHIRE met its primary endpoint in nonambulatory SMA patients receiving standard SMN-targeted therapy, and the drug has been under FDA review with a 2026 action date.
That makes it one of the most important myostatin-pathway candidates, but it is still a disease-specific medical therapy, not a consumer myostatin antibody.
What failed programs taught
The anti-myostatin history has a consistent lesson.
| Lesson | Why it matters |
|---|---|
| Size is not function | MRI volume and DXA lean mass do not guarantee strength or daily benefit |
| Disease matters | Duchenne, SMA, obesity, sarcopenia, and cachexia are different problems |
| Selectivity matters | Blocking related ligands can change safety and efficacy |
| Timing matters | Developmental genetics differ from adult treatment |
| Regulation matters | A research antibody is not an approved drug |
Bottom line
Anti-myostatin antibodies are real, but the category is not a shortcut. Reagent antibodies belong in labs. Therapeutic antibodies belong in trials, regulatory review, or clinician-supervised care for specific indications.
If a sales page treats MYO-029, domagrozumab, trevogrumab, or apitegromab like a normal muscle-building product, it is blurring categories that should stay separate.
Sources and notes
This article was built from SERP review for "anti myostatin" and "anti myostatin antibody" plus clinical and research sources:
- Antimyostatin treatment in health and disease
- MYO-029 trial in adult muscular dystrophies
- Novel myostatin-specific antibody GYM329 research
- Regeneron COURAGE phase 2 trevogrumab results
- Scholar Rock apitegromab 2026 regulatory update
- Thermo Fisher anti-myostatin antibody catalog example
Frequently Asked Questions
Is an anti-myostatin antibody a supplement?
No. Research antibodies are lab reagents, and therapeutic antibodies are biologic drugs. Neither category is a normal supplement.
Did MYO-029 work?
MYO-029 helped test the concept in humans, but it did not become a clear functional treatment breakthrough for muscular dystrophy.
Is apitegromab an anti-myostatin antibody?
It is a myostatin-pathway antibody that targets pro- and latent myostatin. Its main clinical context is spinal muscular atrophy, not bodybuilding.
Can athletes use anti-myostatin antibodies?
Athletes should treat myostatin-pathway drugs as prohibited or high-risk unless their anti-doping authority and prescribing clinician say otherwise for a legitimate medical context.
This article is educational and is not medical advice. Do not use research antibodies, biologics, peptides, or experimental myostatin-pathway products without qualified medical supervision.
